Invivyd, Inc. (IVVD) — Stock Valuation & Research

Adagio Therapeutics, Inc., a biopharmaceutical firm in its clinical development phase, operates within the United States, specializing in the discovery, progression, and marketing of antibody-derived solutions for infectious diseases. The company's leading drug candidate, ADG20 (adintrevimab), is a neutralizing antibody currently undergoing Phase 3 clinical investigation for both the management and prevention of coronavirus disease. Adagio Therapeutics maintains collaborative agreements with Adimab, LLC to facilitate the identification and enhancement of its exclusive antibodies. Furthermore,…

IVVD key statistics

Explore IVVD's full valuation scorecard, price history, financial statements, insider and institutional ownership, and peer comparison on this page — free, no login required.